Scribe Therapeutics Prices Upsized IPO at $15 Per Share to Raise $128.7 Million

Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage biotechnology company, priced its upsized initial public offering of 8,580,000 shares of common stock at $15.00 per share, according to a company press release. The pricing landed at the high end of its expected range, with the offering poised to generate gross proceeds of approximately $128.7 million before underwriting discounts and other expenses.

Offering Details

All shares in the IPO are being offered by Scribe Therapeutics. The company's stock is scheduled to begin trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol "SCTX." The offering is expected to close on July 27, 2026, subject to customary closing conditions.

Underwriters for the deal have been granted a 30-day option to purchase up to an additional 1,287,000 shares at the IPO price. The successful pricing at the top of the projected range, along with the increased size of the offering, suggests significant investor interest in the company's gene-editing platform.

Concurrent Private Placement

Ad

In a concurrent transaction, Scribe Therapeutics has also agreed to a private placement of 500,000 shares to pharmaceutical giant Sanofi at the $15.00 IPO price. This placement is expected to close on July 27, 2026, and is contingent upon the completion of the IPO, though the IPO is not dependent on the private placement.

Company and Market Context

Scribe Therapeutics specializes in developing CRISPR-based genetic medicines, with its initial clinical programs focused on cardiometabolic diseases. The capital raised from the IPO and private placement will likely be used to advance these programs through clinical trials.

The company has existing collaborations with major pharmaceutical firms, including Sanofi and Eli Lilly, which lends credibility to its technology. The offering is being managed by a syndicate of banks, with Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities serving as joint book-running managers.